Opinion|Videos|October 11, 2024
Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
Key Takeaways
- Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment.
- Payers consider clinical outcomes, cost, and value when evaluating belimumab and voclosporin for lupus nephritis management.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Advertisement
Episodes in this series
What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)
How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)
- What does cost-effectiveness look like in LN management?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Closing Reflections on the Future of Vitiligo Care
5